What is Happening to Pacific Biosciences Stock?

April 17. 2024. 6 mins read

Someone once said that bankruptcy happens very slowly, then all of a sudden. That’s about how you’d describe the one stock we held until bankruptcy – Invitae (NVTA) – as it quickly went from growth story to deadly trap. Fortunately, we limit the amount of money we invest in any given stock to avoid chasing falling knives.

Click for PacBio company website

Today, we’re going to discuss a stock we last looked at just over a year ago – Pacific Biosciences (PACB) – a play on the exciting future of long-read sequencing.

The Long-Read Sequencing Thesis

Traditionally, genome sequencing has been performed using short-read sequencing (SRS) machines of the type produced by the undisputed short-read technology leader, Illumina (ILMN). While SRS provides accuracy, a more expensive type of sequencing – long-read sequencing (LRS) – allows for comprehensiveness as the name implies. That’s all set to change according to ARK Invest which expects the cost to sequence a whole human genome with LRS technology will drop to $100-$200, its accuracy superior to SRS across all variant types by the end of 2025. By that time the market will be worth $5 billion which is just over the $4.5 billion Illumina saw in 2023 revenues. Speaking of which, the Illumina Complete L

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.